๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Avoidance of hepatic first-pass effect in the rabbit via rectal route of administration

โœ Scribed by Nahoko Kurosawa; Eiji Owada; Keiji Ito


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
138 KB
Volume
19
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

โœฆ Synopsis


To assess avoidance of hepatic first-pass effect of drugs, we undertook in situ experiments using rectal administration of lidocaine in the rabbit. We also employed in situ duodenal route to estimate first-pass metabolism across the gastrointestinal mucosa. Rabbits were administered lidocaine HCl intravenously (i.v., 50 mg/20 min) and portally (i.p.v., 33.3, 16.7, 8.3 mg/20 min) and avoidance of hepatic first-pass effect (F h ) was calculated from the area under curve (AUC). F h was about 30% and did not vary with increasing i.p.v. dose. Intravenous and i.p.v. administration was followed by duodenal (i.d.) or rectal (i.r.) administration and the absorption (fa), F h , and avoidance of first-pass effect in the duodenal mucosal membrane (F m ) were determined. With i.d. administration, lidocaine was absorbed completely with negligible first-pass effect in the mucosa (F m =1). On the other hand, while lidocaine was also absorbed almost completely via the i.r. route, avoidance of first-pass effect was 60%, representing twice the bioavailability via i.d. administration. On the basis of these data, assuming that the first-pass effect in the rectal mucosa was negligible, we estimate the fraction of rectal venous drainage bypassing the portal circulation and thus hepatic metabolism ( f nh ) to be about 40%.


๐Ÿ“œ SIMILAR VOLUMES


First-pass elimination of lidocaine in t
โœ W. A. Ritschel; H. Elconin; G. J. Alcorn; D. D. Denson ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 400 KB ๐Ÿ‘ 1 views

Lidocaine shows pronounced first-pass metabolism upon peroral administration in man (about 30 per cent peroral bioavailability). Since the rectal bioavailability is about 65 per cent in man it is assumed that some drug is directly absorbed into systemic circulation by-passing the liver. In rats pero

Pharmacokinetics and hepatic first-pass
โœ Inmaculada Soria; Dr. Cheryl L. Zimmerman ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 300 KB ๐Ÿ‘ 1 views

Studies were designed to allow an in vivo estimation of the hepatic extraction ratio and to test the hypothesis that the pharmacokinetic parameters of (-)-CBV are significantly different during anesthesia. (-)-CBV was administered as an IV bolus followed by IV infusion into either the portal (n = 3)

Pharmacokinetics of a new reversible pro
โœ Kye S. Han; Yoon G. Kim; Joong K. Yoo; Jong W. Lee; Myung G. Lee ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 175 KB ๐Ÿ‘ 1 views

The pharmacokinetics of YH1885 were evaluated after intravenous (iv) and oral administrations of the drug to rats and dogs. The reason for the low extent of bioavailability (F) of YH1885 after oral administration of the drug to rats and the absorption of the drug from various rat gastrointestinal (G